Muscular dystrophy (MD) is a spectrum of genetic disorders characterized by muscle weakness that, in severe forms, can lead to loss of ambulation and early mortality. There is a high unmet need for…
Diabetic macular edema (DME) associated with diabetic retinopathy (DR) is a rapidly evolving market as a result of multiple intravitreal (IVT) pharmacotherapy approvals across different drug…
DRG Epidemiology’s coverage of atrial fibrillation comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of atrial fibrillation for…
Clarivate Epidemiology’s coverage of axial spondyloarthritis (AxSpA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AxSpA…
DRG Epidemiology’s coverage of genitourinary syndrome of menopause (GSM) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…
Clarivate Epidemiology’s coverage of axial spondyloarthritis (AxSpA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AxSpA…
Clarivate Epidemiology’s coverage of axial spondyloarthritis (AxSpA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AxSpA…
Clarivate Epidemiology’s coverage of axial spondyloarthritis (AxSpA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AxSpA…
Clarivate Epidemiology’s coverage of axial spondyloarthritis (AxSpA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AxSpA…
Clarivate Epidemiology’s coverage of axial spondyloarthritis (AxSpA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AxSpA…
Since 2018, seven novel drugs have entered the U.S. market for the acute or preventive treatment of migraine, and at least four more are on the short-term horizon. Understanding how prescribers…
The number of prevalent cases of AD in the countries under study will increase by 43% over the 10-year forecast period, from 384,000 to 548,000. Of the countries considered in this analysis,…
DRG Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of key patient populations in the Asia-Pacific region. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of key patient populations in Europe (Austria, Belgium, Czech Republic, Denmark, Finland,…
Clarivate Epidemiology’s coverage of AD comprises epidemiological estimates of key patient populations in the Americas (Argentina, Canada, Chile, Colombia, Peru). We report both the incidence…